Donanemab, the most effective treatment yet for the disease, will be banned on the health service despite regulators ...

The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...

Oct. 17, 2024 — Researchers have cracked the code of plant-to-fungi communication in a new study. Using baker's yeast, the researchers discovered that the plant hormone strigolactone (SL ...

Four anti-amyloid antibodies—lecanemab, aducanumab, gantenerumab, donanemab—cleared plaque from the brain in Phase 3 trials, but only two went on to receive traditional U.S. marketing approval. What ...

Eisai will request a reconsideration of this decision under Section 60* of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in Australia.

Credit: Getty Images As lecanemab becomes more commonly used, its effect on cardiovascular health should be analyzed. The US Food and Drug Administration’s 2023 approval of the anti-amyloid ...

Adding 75mg vial size would achieve greatest reduction in waste, representing annual savings of $99 million. HealthDay News — Annual wasteful spending on discarded lecanemab is anticipated to ...

In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as momentous. Finally, for the first time, a drug had slowed the ...

Lecanemab's weight-based dosing and single-use vials result in significant drug wastage, impacting Medicare spending. An analysis estimated $133 million to $336 million in wasted spending due to ...